Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.

Claus Morten Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Donath

Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.

Translated title of the contribution: Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes

Claus Morten Larsen, Mirjam Faulenbach, Allan Vaag, Aage Vølund, Jan Ehses, Burkhardt Seifert, Thomas Mandrup-Poulsen, Marc Donath

Research output: Contribution to journal › Journal article › Research › peer-review

11 Citations (Scopus)

Abstract

Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation.
Udgivelsesdato: 2007-Nov-5

Translated title of the contribution	Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes
Original language	Danish
Journal	Ugeskrift for læger
Volume	169
Issue number	45
Pages (from-to)	3868-71
Number of pages	3
ISSN	0041-5782
Publication status	Published - 2007

Cite this

@article{e7035300acd111ddb538000ea68e967b,

title = "Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.",

abstract = "Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5",

author = "Larsen, {Claus Morten} and Mirjam Faulenbach and Allan Vaag and Aage V{\o}lund and Jan Ehses and Burkhardt Seifert and Thomas Mandrup-Poulsen and Marc Donath",

year = "2007",

language = "Dansk",

volume = "169",

pages = "3868--71",

journal = "Ugeskrift for l{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "45",

}

TY - JOUR

T1 - Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.

AU - Larsen, Claus Morten

AU - Faulenbach, Mirjam

AU - Vaag, Allan

AU - Vølund, Aage

AU - Ehses, Jan

AU - Seifert, Burkhardt

AU - Mandrup-Poulsen, Thomas

AU - Donath, Marc

PY - 2007

Y1 - 2007

N2 - Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5

AB - Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5

M3 - Tidsskriftartikel

C2 - 18031661

SN - 0041-5782

VL - 169

SP - 3868

EP - 3871

JO - Ugeskrift for læger

JF - Ugeskrift for læger

IS - 45

ER -